Downtown San Francisco
San Francisco — Amongst all the chaos and frenetic activity that abounds big Pharma at JPM each year, I always look forward to hearing what the smaller biotechs are up to on days 3 and 4, as well as seeing how far some of them have progressed since our previous update on their pipeline agents.
In this latest update, there are definitely some companies we have been following longitudinally who are either poised for future success and growth… or due for a correction if the promising science doesn’t pan out as expected in the clinic.
Indeed one of those companies has already hit success and disappointment in the last two months alone, such is the roller coaster that is oncology R&D.
Please note that this is a rolling blog, which means that numerous updates are added throughout the day as new information becomes available.
To learn more from our oncology coverage and get a heads up on our latest commentary JPM annual meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
Times Square, New York
New York – Every now and then you go to a cancer conference and instead of hearing the expected standard talk that is repeated time and time again for a season or so, you are delighted with a more engaging and uninhibited approach that captivates and informs on the latest state of the art progress.
It also means that more than the presenter realises is perhaps shared. That’s very good news indeed for intrepid science writers and anyone who cares to listen or read.
The research mentioned in today’s post falls in the engaged and delighted category…
To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.